Android Apple

DRI Healthcare Trust Acquires Royalty in Pre-Approval Sebetralstat for Up to $179 Mln

By MarketWatch   |   1 month ago
DRI Healthcare Trust Acquires Royalty in Pre-Approval Sebetralstat for Up to $179 Mln

DRI Healthcare Trust bought a royalty interest in Sebetralstat, a drug for hereditary angioedema, for $179 million. The drug is in the approval process with the FDA and EMA, potentially becoming the first oral therapy for this condition.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.